Inhibition of SIRT1 impairs the accumulation and transcriptional activity of HIF-1α protein under hypoxic conditions

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Laemmle, Alexander ^a   Lechleiter, Antje ^a   Roh, Vincent ^a,b   Schwarz, Christa ^a   Portmann, Simone ^a   Furer, Cynthia ^a   Keogh, Adrian ^a   Tschan, Mario P ^a   Candinas, Daniel ^a   Vorburger, Stephan A ^a,c   Stroka, Deborah ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c Regionalspital Emmental AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

2 NAPHTHOL; CAMBINOL; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; SHORT HAIRPIN RNA; SIRTINOL; SIRTUIN 1; UNCLASSIFIED DRUG; BENZAMIDE DERIVATIVE; HIF1A PROTEIN, HUMAN; NAPHTHALENE DERIVATIVE; NAPHTHOL DERIVATIVE; PYRIMIDINONE DERIVATIVE; SIRT1 PROTEIN, HUMAN;

ACETYLATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; GENE CONTROL; GENE TARGETING; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; TRANSCRIPTION REGULATION; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; ANOXIA; CELL HYPOXIA; CELL STRAIN HEPG2; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; GENE EXPRESSION REGULATION; GENETICS; LIVER TUMOR; METABOLISM; MOUSE MUTANT; NUDE MOUSE; PATHOLOGY; PROTEIN BINDING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TRANSCRIPTION INITIATION; TUMOR CELL LINE; TUMOR VOLUME; WESTERN BLOTTING; XENOGRAFT;

ANIMALS; ANOXIA; BENZAMIDES; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL HYPOXIA; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, KNOCKOUT; MICE, NUDE; NAPHTHALENES; NAPHTHOLS; PROTEIN BINDING; PYRIMIDINONES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIRTUIN 1; TRANSCRIPTIONAL ACTIVATION; TRANSPLANTATION, HETEROLOGOUS; TUMOR BURDEN;

EID: 84859113488     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0033433     Document Type: Article

References (71)

1. Rine J, Herskowitz I, (1987) Four genes responsible for a position effect on expression from HML and HMR in Saccharomyces cerevisiae. Genetics 116: 9-22.
2. Imai S, Armstrong CM, Kaeberlein M, Guarente L, (2000) Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 403: 795-800.
3. Tanner KG, Landry J, Sternglanz R, Denu JM, (2000) Silent information regulator 2 family of NAD- dependent histone/protein deacetylases generates a unique product, 1-O-acetyl-ADP-ribose. Proc Natl Acad Sci U S A 97: 14178-14182.
4. Yu J, Auwerx J, (2009) The role of sirtuins in the control of metabolic homeostasis. Annals of the New York Academy of Sciences 1173 (Suppl 1): E10-19.
5. North BJ, Marshall BL, Borra MT, Denu JM, Verdin E, (2003) The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. Molecular Cell 11: 437-444.
6. Onyango P, Celic I, McCaffery JM, Boeke JD, Feinberg AP, (2002) SIRT3, a human SIR2 homologue, is an NAD-dependent deacetylase localized to mitochondria. Proc Natl Acad Sci U S A 99: 13653-13658.
7. Nakagawa T, Lomb DJ, Haigis MC, Guarente L, (2009) SIRT5 Deacetylates carbamoyl phosphate synthetase 1 and regulates the urea cycle. Cell 137: 560-570.
8. Du J, Zhou Y, Su X, Yu JJ, Khan S, et al. (2011) Sirt5 is a NAD-dependent protein lysine demalonylase and desuccinylase. Science 334: 806-809.
9. Haigis MC, Mostoslavsky R, Haigis KM, Fahie K, Christodoulou DC, et al. (2006) SIRT4 inhibits glutamate dehydrogenase and opposes the effects of calorie restriction in pancreatic beta cells. Cell 126: 941-954.
10. Michishita E, McCord RA, Berber E, Kioi M, Padilla-Nash H, et al. (2008) SIRT6 is a histone H3 lysine 9 deacetylase that modulates telomeric chromatin. Nature 452: 492-496.
11. Mostoslavsky R, Chua KF, Lombard DB, Pang WW, Fischer MR, et al. (2006) Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. Cell 124: 315-329.
12. Ford E, Voit R, Liszt G, Magin C, Grummt I, et al. (2006) Mammalian Sir2 homolog SIRT7 is an activator of RNA polymerase I transcription. Genes & Development 20: 1075-1080.
13. Kaeberlein M, McVey M, Guarente L, (1999) The SIR2/3/4 complex and SIR2 alone promote longevity in Saccharomyces cerevisiae by two different mechanisms. Genes & Development 13: 2570-2580.
14. Tissenbaum HA, Guarente L, (2001) Increased dosage of a sir-2 gene extends lifespan in Caenorhabditis elegans. Nature 410: 227-230.
15. Rogina B, Helfand SL, (2004) Sir2 mediates longevity in the fly through a pathway related to calorie restriction. Proc Natl Acad Sci U S A 101: 15998-16003.
16. Cohen HY, Miller C, Bitterman KJ, Wall NR, Hekking B, et al. (2004) Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science 305: 390-392.
17. Burnett C, Valentini S, Cabreiro F, Goss M, Somogyvari M, et al. (2011) Absence of effects of Sir2 overexpression on lifespan in C. elegans and Drosophila. Nature 477: 482-485.
18. Fang Y, Nicholl MB, (2011) Sirtuin 1 in malignant transformation: friend or foe? Cancer Letters 306: 10-14.
19. Landry J, Sutton A, Tafrov ST, Heller RC, Stebbins J, et al. (2000) The silencing protein SIR2 and its homologs are NAD-dependent protein deacetylases. Proc Natl Acad Sci U S A 97: 5807-5811.
20. Luo J, Nikolaev AY, Imai S, Chen D, Su F, et al. (2001) Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 107: 137-148.
21. Vaziri H, Dessain SK, Ng Eaton E, Imai SI, Frye RA, et al. (2001) hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 107: 149-159.
22. Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, et al. (2004) Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 303: 2011-2015.
23. Jeong J, Juhn K, Lee H, Kim SH, Min BH, et al. (2007) SIRT1 promotes DNA repair activity and deacetylation of Ku70. Exp Mol Med 39: 8-13.
24. Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, et al. (2004) Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J 23: 2369-2380.
25. Wang C, Chen L, Hou X, Li Z, Kabra N, et al. (2006) Interactions between E2F1 and SirT1 regulate apoptotic response to DNA damage. Nat Cell Biol 8: 1025-1031.
26. Nemoto S, Fergusson MM, Finkel T, (2005) SIRT1 functionally interacts with the metabolic regulator and transcriptional coactivator PGC-1{alpha}. The Journal of Biological Chemistry 280: 16456-16460.
27. Lim JH, Lee YM, Chun YS, Chen J, Kim JE, et al. (2010) Sirtuin 1 modulates cellular responses to hypoxia by deacetylating hypoxia-inducible factor 1alpha. Molecular Cell 38: 864-878.
28. Dioum EM, Chen R, Alexander MS, Zhang Q, Hogg RT, et al. (2009) Regulation of hypoxia-inducible factor 2alpha signaling by the stress-responsive deacetylase sirtuin 1. Science 324: 1289-1293.
29. Huang LE, Arany Z, Livingston DM, Bunn HF, (1996) Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit. The Journal of Biological Chemistry 271: 32253-32259.
30. Bruick RK, McKnight SL, (2001) A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294: 1337-1340.
31. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, et al. (2001) Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292: 468-472.
32. Ivan M, Kondo K, Yang H, Kim W, Valiando J, et al. (2001) HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 292: 464-468.
33. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, et al. (1999) The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399: 271-275.
34. Semenza GL, Wang GL, (1992) A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 12: 5447-5454.
35. Hu CJ, Wang LY, Chodosh LA, Keith B, Simon MC, (2003) Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol Cell Biol 23: 9361-9374.
36. Raval RR, Lau KW, Tran MG, Sowter HM, Mandriota SJ, et al. (2005) Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol 25: 5675-5686.
37. Sowter HM, Raval RR, Moore JW, Ratcliffe PJ, Harris AL, (2003) Predominant role of hypoxia-inducible transcription factor (Hif)-1alpha versus Hif-2alpha in regulation of the transcriptional response to hypoxia. Cancer Research 63: 6130-6134.
38. Zhong L, D'Urso A, Toiber D, Sebastian C, Henry RE, et al. (2010) The histone deacetylase Sirt6 regulates glucose homeostasis via Hif1alpha. Cell 140: 280-293.
39. Finley LW, Carracedo A, Lee J, Souza A, Egia A, et al. (2011) SIRT3 opposes reprogramming of cancer cell metabolism through HIF1alpha destabilization. Cancer Cell 19: 416-428.
40. Chen R, Dioum EM, Hogg RT, Gerard RD, Garcia JA, (2011) Hypoxia increases sirtuin 1 expression in a hypoxia-inducible factor-dependent manner. The Journal of Biological Chemistry 286: 13869-13878.
41. Grozinger CM, Chao ED, Blackwell HE, Moazed D, Schreiber SL, (2001) Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening. The Journal of Biological Chemistry 276: 38837-38843.
42. Camenisch G, Stroka DM, Gassmann M, Wenger RH, (2001) Attenuation of HIF-1 DNA-binding activity limits hypoxia-inducible endothelin-1 expression. Pflugers Archiv: European Journal of Physiology 443: 240-249.
43. Camenisch G, Tini M, Chilov D, Kvietikova I, Srinivas V, et al. (1999) General applicability of chicken egg yolk antibodies: the performance of IgY immunoglobulins raised against the hypoxia-inducible factor 1alpha. FASEB J 13: 81-88.
44. Krieg M, Haas R, Brauch H, Acker T, Flamme I, et al. (2000) Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Oncogene 19: 5435-5443.
45. Wykoff CC, Pugh CW, Maxwell PH, Harris AL, Ratcliffe PJ, (2000) Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling. Oncogene 19: 6297-6305.
46. Potente M, Ghaeni L, Baldessari D, Mostoslavsky R, Rossig L, et al. (2007) SIRT1 controls endothelial angiogenic functions during vascular growth. Genes & Development 21: 2644-2658.
47. Heltweg B, Gatbonton T, Schuler AD, Posakony J, Li H, et al. (2006) Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. Cancer Research 66: 4368-4377.
48. Stroka DM, Burkhardt T, Desbaillets I, Wenger RH, Neil DA, et al. (2001) HIF-1 is expressed in normoxic tissue and displays an organ-specific regulation under systemic hypoxia. FASEB J 15: 2445-2453.
49. Bangoura G, Liu ZS, Qian Q, Jiang CQ, Yang GF, et al. (2007) Prognostic significance of HIF-2alpha/EPAS1 expression in hepatocellular carcinoma. World Journal of Gastroenterology 13: 3176-3182.
50. Xie H, Song J, Liu K, Ji H, Shen H, et al. (2008) The expression of hypoxia-inducible factor-1alpha in hepatitis B virus-related hepatocellular carcinoma: correlation with patients' prognosis and hepatitis B virus X protein. Digestive Diseases and Sciences 53: 3225-3233.
51. Rane S, He M, Sayed D, Vashistha H, Malhotra A, et al. (2009) Downregulation of miR-199a derepresses hypoxia-inducible factor-1alpha and Sirtuin 1 and recapitulates hypoxia preconditioning in cardiac myocytes. Circulation Research 104: 879-886.
52. Bilton R, Trottier E, Pouyssegur J, Brahimi-Horn MC, (2006) ARDent about acetylation and deacetylation in hypoxia signalling. Trends Cell Biol 16: 616-621.
53. Jeong JW, Bae MK, Ahn MY, Kim SH, Sohn TK, et al. (2002) Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell 111: 709-720.
54. Arnesen T, Kong X, Evjenth R, Gromyko D, Varhaug JE, et al. (2005) Interaction between HIF-1 alpha (ODD) and hARD1 does not induce acetylation and destabilization of HIF-1 alpha. FEBS Letters 579: 6428-6432.
55. Bilton R, Mazure N, Trottier E, Hattab M, Dery MA, et al. (2005) Arrest-defective-1 protein, an acetyltransferase, does not alter stability of hypoxia-inducible factor (HIF)-1alpha and is not induced by hypoxia or HIF. The Journal of Biological Chemistry 280: 31132-31140.
56. Wei W, Yu XD, (2007) Hypoxia-inducible factors: crosstalk between their protein stability and protein degradation. Cancer Letters 257: 145-156.
57. Berra E, Benizri E, Ginouves A, Volmat V, Roux D, et al. (2003) HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. EMBO J 22: 4082-4090.
58. Luo W, Hu H, Chang R, Zhong J, Knabel M, et al. (2011) Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell 145: 732-744.
59. Hitosugi T, Kang S, Vander Heiden MG, Chung TW, Elf S, et al. (2009) Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Science Signaling 2: ra73.
60. Spoden GA, Morandell D, Ehehalt D, Fiedler M, Jansen-Durr P, et al. (2009) The SUMO-E3 ligase PIAS3 targets pyruvate kinase M2. Journal of Cellular Biochemistry 107: 293-302.
61. Zhao S, Xu W, Jiang W, Yu W, Lin Y, et al. (2010) Regulation of cellular metabolism by protein lysine acetylation. Science 327: 1000-1004.
62. Iyer NV, Kotch LE, Agani F, Leung SW, Laughner E, et al. (1998) Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. Genes & Development 12: 149-162.
63. Chen J, Zhang B, Wong N, Lo AW, To KF, et al. (2011) Sirtuin 1 is upregulated in a subset of hepatocellular carcinomas where it is essential for telomere maintenance and tumor cell growth. Cancer Research 71: 4138-4149.
64. Huffman DM, Grizzle WE, Bamman MM, Kim JS, Eltoum IA, et al. (2007) SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer Research 67: 6612-6618.
65. Lee IH, Cao L, Mostoslavsky R, Lombard DB, Liu J, et al. (2008) A role for the NAD-dependent deacetylase Sirt1 in the regulation of autophagy. Proc Natl Acad Sci U S A 105: 3374-3379.
66. Schlicker C, Boanca G, Lakshminarasimhan M, Steegborn C, (2011) Structure-based development of novel sirtuin inhibitors. Aging 3: 852-872.
67. Semenza GL, (2010) Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 29: 625-634.
68. Stein S, Schafer N, Breitenstein A, Besler C, Winnik S, et al. (2010) SIRT1 reduces endothelial activation without affecting vascular function in ApoE-/- mice. Aging 2: 353-360.
69. Karin M, Cao Y, Greten FR, Li ZW, (2002) NF-kappaB in cancer: from innocent bystander to major culprit. Nature Reviews Cancer 2: 301-310.
70. Kim HS, Patel K, Muldoon-Jacobs K, Bisht KS, Aykin-Burns N, et al. (2010) SIRT3 is a mitochondria-localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress. Cancer Cell 17: 41-52.
71. Tschan MP, Fischer KM, Fung VS, Pirnia F, Borner MM, et al. (2003) Alternative splicing of the human cyclin D-binding Myb-like protein (hDMP1) yields a truncated protein isoform that alters macrophage differentiation patterns. The Journal of Biological Chemistry 278: 42750-42760.